View More Recent Stories

May 13, 2025 06:57AM Dianthus Therapeutics (DNTH) Misses Q1 EPS by 82c
May 5, 2025 07:02AM Dianthus Therapeutics (DNTH) Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
Mar 12, 2025 07:39AM Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
Mar 12, 2025 06:33AM Dianthus Therapeutics (DNTH) Misses Q4 EPS by 81c
Mar 5, 2025 07:02AM Dianthus Therapeutics (DNTH) Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango to Board
Dec 20, 2024 05:31AM TD Cowen Starts Dianthus Therapeutics (DNTH) at Buy
Nov 11, 2024 07:51AM Dianthus Therapeutics (DNTH) PT Raised to $52 at Oppenheimer
Nov 8, 2024 06:24AM Dianthus Therapeutics (DNTH) Misses Q3 EPS by 74c
Oct 7, 2024 06:54AM Baird Reiterates Outperform Rating on Dianthus Therapeutics (DNTH)
Oct 4, 2024 10:10AM Guggenheim Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
Oct 1, 2024 04:38PM Dianthus Therapeutics (DNTH) Files $500M Mixed Shelf
Oct 1, 2024 04:34PM Dianthus Therapeutics (DNTH) Files for 23.66M Share Offering by Selling Stockholders
Sep 26, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
Aug 9, 2024 06:38AM Dianthus Therapeutics (DNTH) Misses Q2 EPS by 51c
Jul 26, 2024 04:58AM Baird Starts Dianthus Therapeutics (DNTH) at Outperform
Jun 12, 2024 07:00AM Dianthus Therapeutics (DNTH) Granted FDA Clearance to Initiate Phase 2 Trial of DNTH103
View More Recent Stories